UFIS-SWE-IG
0.1.0 - ci-build
UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions
Generated Narrative: MedicinalProductDefinition Oxascand-10mg-Tablet-SE-IS-MPD
identifier: http://ema.europa.eu/fhir/mpId
/SE-100001594-00010743, http://ema.europa.eu/fhir/eurdId
/2234
domain: Human use
status: Current
combinedPharmaceuticalDoseForm: Tablet
indication:
Oxascand påverkar de vid ångestsyndrom vanliga symtomen: ängslan, ångest, rastlöshet och sömnsvårigheter. Vid depressioner med inslag av nyss nämnda symtom kan Oxascand användas tillsammans med sedvanliga antidepressiva farmaka. Delirium tremens, predeliriösa tillstånd och akuta abstinenssymtom som ångest, spänning och excitation i samband med alkoholmissbruk.
legalStatusOfSupply: Medicinal product subject to special medical prescription
classification: N05BA04
name
productName: Oxascand 10 mg Tablett
part
part: Oxascand
type: Invented name part
part
part: 10 mg
type: Strength part
part
part: Tablett
type: Pharmaceutical dose form part
Usages
Country Language Kingdom of Sweden Swedish